IMUNON Announces Stock Dividend Boosting Shareholder Value
IMUNON (NASDAQ:IMNN) has announced a 15% stock dividend, distributing approximately 448,000 additional shares to shareholders of record as of August 7, 2025. The distribution is scheduled for August 21, 2025.
The company's decision reflects confidence in its clinical programs, particularly the IMNN-001 program for advanced ovarian cancer, which recently reported strong Phase 2 results and is advancing to Phase 3 trials. CEO Stacy R. Lindborg emphasized that this move demonstrates their commitment to shareholder value while advancing their innovative pipeline.
IMUNON (NASDAQ:IMNN) ha annunciato un dividendo azionario del 15%, distribuendo circa 448.000 azioni aggiuntive agli azionisti registrati al 7 agosto 2025. La distribuzione è prevista per il 21 agosto 2025.
La decisione dell'azienda riflette la fiducia nei suoi programmi clinici, in particolare nel programma IMNN-001 per il carcinoma ovarico avanzato, che ha recentemente riportato risultati positivi nella Fase 2 e sta procedendo verso la Fase 3. La CEO Stacy R. Lindborg ha sottolineato che questa mossa dimostra il loro impegno nel creare valore per gli azionisti, continuando a sviluppare la loro pipeline innovativa.
IMUNON (NASDAQ:IMNN) ha anunciado un dividendo en acciones del 15%, distribuyendo aproximadamente 448,000 acciones adicionales a los accionistas registrados al 7 de agosto de 2025. La distribución está programada para el 21 de agosto de 2025.
La decisión de la compañía refleja confianza en sus programas clínicos, especialmente en el programa IMNN-001 para cáncer de ovario avanzado, que recientemente reportó resultados sólidos en la Fase 2 y avanza hacia ensayos de Fase 3. La CEO Stacy R. Lindborg enfatizó que esta acción demuestra su compromiso con el valor para los accionistas mientras impulsan su innovadora cartera de proyectos.
IMUNON (NASDAQ:IMNN)은 15% 주식 배당을 발표했으며, 2025년 8월 7일 기준 주주들에게 약 448,000주의 추가 주식을 배포할 예정입니다. 배당은 2025년 8월 21일에 진행됩니다.
회사는 임상 프로그램, 특히 진행성 난소암을 위한 IMNN-001 프로그램에 대한 자신감을 반영한 결정이며, 이 프로그램은 최근 2상 시험에서 우수한 결과를 보고하고 3상 시험으로 진입 중입니다. CEO Stacy R. Lindborg는 이번 조치가 혁신적인 파이프라인을 발전시키면서 주주 가치를 증대하려는 의지를 보여준다고 강조했습니다.
IMUNON (NASDAQ:IMNN) a annoncé un dividende en actions de 15%, distribuant environ 448 000 actions supplémentaires aux actionnaires inscrits au 7 août 2025. La distribution est prévue pour le 21 août 2025.
La décision de la société reflète sa confiance dans ses programmes cliniques, notamment le programme IMNN-001 pour le cancer ovarien avancé, qui a récemment présenté d'excellents résultats en phase 2 et progresse vers les essais de phase 3. La PDG Stacy R. Lindborg a souligné que cette initiative démontre leur engagement envers la création de valeur pour les actionnaires tout en faisant avancer leur pipeline innovant.
IMUNON (NASDAQ:IMNN) hat eine 15%ige Aktiendividende angekündigt und verteilt etwa 448.000 zusätzliche Aktien an die zum 7. August 2025 eingetragenen Aktionäre. Die Ausschüttung ist für den 21. August 2025 geplant.
Die Entscheidung des Unternehmens spiegelt das Vertrauen in seine klinischen Programme wider, insbesondere das IMNN-001-Programm für fortgeschrittenen Eierstockkrebs, das kürzlich starke Ergebnisse in Phase 2 meldete und nun in Phase 3 übergeht. CEO Stacy R. Lindborg betonte, dass dieser Schritt ihr Engagement für den Shareholder Value unterstreicht und gleichzeitig ihre innovative Pipeline vorantreibt.
- Stock dividend of 15% demonstrates confidence in company's future
- IMNN-001 program reported strong Phase 2 clinical data in ovarian cancer
- Advancement to Phase 3 pivotal trial for lead program
- No action required from shareholders for dividend distribution
- Stock dividend may not add real economic value as it simply splits existing equity
- Phase 3 trial outcomes remain uncertain
Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders
LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that its Board of Directors approved a
The stock dividend program will distribute a total of approximately 448,000 shares of additional shares of IMUNON common stock for each share (or common stock equivalent) held, payable to such holders of record as of August 7, 2025. The distribution is expected to occur on August 21, 2025. Stockholders will not be required to take any action to receive the dividend. After the payment date, stockholders’ book entry accounts will be credited with the additional shares that represent the stock dividend. When shares are held in a brokerage account in the name of a broker, the additional shares will be distributed to the broker on the stockholder’s behalf. The stock dividend is administered by Equiniti Trust Company, the Company’s transfer agent.
“We are pleased to announce this stock dividend as a way to share our recent clinical progress and optimism with our shareholders,” said Stacy R. Lindborg, President and CEO of IMUNON. “This action underscores our commitment to creating value while we continue to advance our innovative pipeline of therapies aimed at addressing critical unmet medical needs, including our lead IMNN-001 program in advanced ovarian cancer that recently reported unprecedented Phase 2 clinical data and is currently advancing in a Phase 3 pivotal trial.”
IMUNON remains focused on its mission to develop transformative treatments, with ongoing clinical programs. The Company believes this stock dividend will further align its shareholder base with its vision for sustained growth and innovation.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), and include statements regarding our planned stock split. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to the reverse stock split having the desired effect, our ability to regain compliance with Nasdaq’s listing requirements, the potential de-listing of our shares on Nasdaq, risks and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG Life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
What is the IMNN stock dividend ratio announced for 2025?
When will IMUNON (IMNN) distribute the stock dividend in 2025?
How many additional IMNN shares will be distributed in the stock dividend?
What is the current status of IMUNON's IMNN-001 cancer program?
Do IMUNON shareholders need to take any action to receive the stock dividend?
